Variants of hepatitis B virus resistant against some nucleoside analogues, but sensitive to others, and uses thereof

US7807437B2 · kind B2 · utility

Assignees

• Rheinische Friedrich-Wilhems-Universitaet Bonn · DE
• UNIVERSITAET ZU KOELN · DE
• JUSTUS-LIEBIG-UNIVERSITAET GIESSEN · DE

Inventors

• Oliver Schildgen · Cologne, DE
• Martin Vogel · Bonn, DE
• Bertfried Matz · Bonn, DE
• Juergen Rockstroh · Cologne, DE
• Rolf Kaiser · Augsburg, DE
• Martin Daeumer · Bonn, DE
• Martin Helm · Nuremberg, DE
• Lutwin Weitner · Hamburg, DE
• Carl Knud Schewe · Hamburg, DE
• Wolfram Gerlich · Marburg, DE

Key dates

• Filing date: Mar 15, 2006
• Grant date: Oct 5, 2010
• Expiry date: Mar 15, 2026

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2333/02
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

The present invention relates generally to the field of Hepatitis B variants exhibiting a reduced sensitivity to nucleoside analogues both in vivo and in vitro. More in particular, reverse transcriptase mutant rt I233V is provided. Present invention provides assays and methods for detecting such variant, which assays are useful in monitoring anti-viral therapeutic regimes and adjusting patient therapy. A diagnostic kit for detecting the presence of an HBV variant in a biological sample has also been described. Finally, the use of a pharmaceutical composition to cure a subject suffering from a HBV infection, which HBV is resistant to lamuvidine and/or adefovir has been provided, which pharmaceutical composition comprises the nucleoside analogue tenofovir.